Literature DB >> 9088497

Myeloneuropathy from whipped cream bulbs presenting as conversion disorder.

A Brett1.   

Abstract

OBJECTIVE: To highlight the complications of nitrous oxide abuse. CLINICAL PICTURE: A case is presented of a myeloneuropathy in a 21-year-old woman who had been abusing nitrous oxide, obtained from whipped cream bulbs, who was referred to a psychiatric hospital with a diagnosis of conversion disorder. Nitrous oxide toxicity has been reported in medical and dental professions and a few cases of myeloneuropathy due to induced vitamin B12 deficiency have been reported. This would appear to be the first reported case of myeloneuropathy resulting from nitrous oxide abuse from whipped cream propellants as a recreational drug in the community. TREATMENT: Three doses of intramuscular hydroxy cobalamin (1000 micrograms) over the course of 1 week. OUTCOME: Her neurological symptoms and anxiety settled.
CONCLUSIONS: Nitrous oxide is becoming more popular as a recreational drug; its complications should be noted and a thorough neurological examination performed if abuse is suspected.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088497     DOI: 10.3109/00048679709073810

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  2 in total

1.  Psychiatric disorders in inhalant users: results from The National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Li-Tzy Wu; Matthew Owen Howard
Journal:  Drug Alcohol Depend       Date:  2006-11-28       Impact factor: 4.492

2.  The MEOPAeDent trial protocol-an observational study of the Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) effects in paediatric dentistry.

Authors:  Tony Prud'homme; Sylvie Dajean-Trutaud; Morgane Rousselet; Fanny Feuillet; Marjorie Carpentier-Cheraud; Olivier Bonnot; Isabelle Hyon; Marie Grall-Bronnec; Serena Lopez-Cazaux; Caroline Victorri-Vigneau
Journal:  BMC Oral Health       Date:  2019-03-07       Impact factor: 2.757

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.